Acknowledgement
This research was supported by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education (2020R1l1A3072212) and by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT, 2023R1A2C1003481).
References
- Xiaoguang C, Hongyan L, Xiaohong L, Zhaodi F, Yan L, Lihua T, Rui H. Cancer chemopreventive and therapeutic activities of red ginseng. J Ethnopharmacol 1998;60(1):71-8. https://doi.org/10.1016/S0378-8741(97)00133-5
- Kim JH, Hahm DH, Yang DC, Kim JH, Lee HJ, Shim I. Effect of crude saponin of Korean Red Ginseng on high-fat diet-induced obesity in the rat. J Pharmacol Sci 2005;97(1):124-31. https://doi.org/10.1254/jphs.FP0040184
- Li R. Natural product-based drug discovery. Med Res Rev 2016;36(1):3.
- Oliynyk S, Oh S. Actoprotective effect of ginseng: improving mental and physical performance. J Ginseng Res 2013 Apr;37(2):144-66. https://doi.org/10.5142/jgr.2013.37.144
- Lee R, Kim JH, Hwang H, Rhim H, Hwang SH, Cho IH, Kim DG, Kim HC, Nah SY. Preparation of red ginseng marc-derived gintonin and its application as a skin nutrient. Nutrients 2023;15(11):2574.
- Choi SH, Hong MK, Kim HJ, Ryoo N, Rhim H, Nah SY, Kang LW. Structure of ginseng major latex-like protein 151 and its proposed lysophosphatidic acid-binding mechanism. Acta Crystallogr D Biol Crystallogr 2015;71(Pt 5):1039-50. https://doi.org/10.1107/S139900471500259X
- Choi JH, Jang M, Oh S, Nah SY, Cho IH. Multi-target protective effects of gintonin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated model of Parkinson's disease via lysophosphatidic acid receptors. Front Pharmacol 2018;9:515.
- Hwang SH, Shin EJ, Shin TJ, Lee BH, Choi SH, Kang J, Kim HJ, Kwon SH, Jang CG, Lee JH, Kim HC, Nah SY. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing. J Alzheimers Dis 2012;31(1):207-23. https://doi.org/10.3233/JAD-2012-120439
- Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. Cancer Sci 2017;108(10):1974-84. https://doi.org/10.1111/cas.13337
- Liu X, Zhang Z, Liu J, Wang Y, Zhou Q, Wang S, Wang X. Ginsenoside Rg3 improves cyclophosphamide-induced immunocompetence in Balb/c mice. Int Immunopharm 2019;72:98-111. https://doi.org/10.1016/j.intimp.2019.04.003
- Oliynyk S, Oh S. Actoprotective effect of ginseng: improving mental and physical performance. J Ginseng Res 2013;37(2):144-66. 2013 Apr. https://doi.org/10.5142/jgr.2013.37.144
- Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997;15:297-322. https://doi.org/10.1146/annurev.immunol.15.1.297
- Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111-47. https://doi.org/10.1016/S0065-2776(08)60652-5
- Lee Y, Park A, Park YJ, Jung H, Kim TD, Noh JY, Chio I, Lee S, Yoon SR. Ginsenoside 20(R)-Rg3 enhances natural killer cell activity by increasing activating receptor expression through the MAPK/ERK signaling pathway. Int Immunopharm 2022;107:108618.
- Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22(11):633-40. https://doi.org/10.1016/S1471-4906(01)02060-9
- Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Alisa BL, Blazar BR, Cornfield DN, Miller JS, Verneris MR. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood 2007 Sep 1;110(5):530-1539. https://doi.org/10.1182/blood.V110.11.530.530
- Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, Gwynne S, Blount D, Harrop R, Hills R, Gallimore A, Godkin A. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin Cancer Res 2017 Nov 15;23(22):6771-80. https://doi.org/10.1158/1078-0432.CCR-17-0895
- Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641-8. https://doi.org/10.1007/s00262-006-0225-8